Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development

Why It Matters

The collaboration streamlines a complex, high‑cost segment of vaccine manufacturing, enabling faster development cycles and broader access to conjugate vaccines—a critical tool in preventing bacterial diseases worldwide.

Key Takeaways

• Intravacc and Primrose Bio renew partnership to offer end‑to‑end vaccine services
• PeliCRM197® carrier protein now available in GMP‑grade kilogram batches
• Combined expertise covers preclinical, scale‑up, and clinical manufacturing phases
• Partnership fills a gap for early‑stage developers needing conjugation solutions
• Access to ultra‑pure carrier protein aims to accelerate global vaccine pipelines

Pulse Analysis

Conjugate vaccines, which link a polysaccharide antigen to a protein carrier, have become essential tools in preventing bacterial diseases such as meningitis, pneumonia, and typhoid. Their ability to provoke strong, long‑lasting immune responses in infants and the elderly has driven a surge in R&D pipelines worldwide. Yet the manufacturing process is technically demanding, requiring precise conjugation chemistry, stringent purification, and compliance with Good Manufacturing Practice (GMP) standards. As governments and NGOs push for broader immunization coverage, contract development and manufacturing organizations (CDMOs) that can streamline these steps are in high demand.

Intravacc, a European CDMO with deep vaccine expertise, and Primrose Bio, the developer of the PeliCRM197® carrier protein, have renewed their strategic alliance to deliver a full‑service solution for conjugate vaccine developers. Primrose supplies ultra‑pure CRM197 in quantities ranging from milligrams for research to kilograms for commercial GMP production, while Intravacc handles antigen conjugation, process scale‑up, and regulatory filing. By integrating Primrose’s proprietary carrier with Intravacc’s state‑of‑the‑art facilities, the partnership reduces hand‑offs, shortens timelines, and offers clients a single point of contact for end‑to‑end development.

The collaboration addresses a critical bottleneck for early‑stage biotech firms that lack in‑house conjugation capacity. Faster access to GMP‑grade carrier protein and a proven manufacturing pathway can accelerate candidate selection and move projects into clinical trials more efficiently. Industry analysts anticipate that the combined offering will attract not only traditional vaccine makers but also emerging players targeting novel bacterial antigens and antimicrobial‑resistant strains. As the global conjugate vaccine market is projected to exceed $10 billion by 2030, Intravacc and Primrose Bio’s renewed partnership positions both companies to capture a larger share of this growth.